A review on potential adverse effects associated with Janus-kinase inhibitors
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20241006Keywords:
JAKI’s, Rheumatoid arthritis, DMARD’s, Safety, Efficacy, PharmacotherapyAbstract
Rheumatoid arthritis (RA) is a chronic, symmetrical, inflammatory autoimmune disease that affects small joints. RA has a population prevalence of 0.5% to 1% in the U.S. The annual cost of care for chronic treatment of RA in the United States is estimated at $12,509. Pharmaceutical companies have developed drugs to treat RA using Janus kinase (JAK) inhibitors. These drugs can have potential adverse effects. Forecasting a better output to JAK inhibitors (JAKI’s). Therapy duration of JAKI’s and Problems regarding to strategies of dose reduction or if the discontinuation of therapy takes place in case of low disease activity. The accurate pharmacological profile and interactions of other drugs with JAKI’s have to establish. Proper safety, efficacy profile of JAKI’s and when administered in combination with DMARD’s. The safety, efficacy data of JAKI’s when compared to non-anti-TNF biologics. Obtaining of experience on JAKI’s that were already existed in the market and further experimental findings on newer compounds and which may clarify many of the aspects which are to be solved in nearer future as these JAKI will have greater application in treatment of RA. Regardless of significant developments in latest years in the pharmacotherapy of RA in the use of JAK inhibitors, yet the adverse effects of JAK inhibitors are unanswered. Therefore, one of the main concerns associated with JAK inhibitor is the potential adverse effects. The challenges can be addressed by clinical pharmacist mediated interventions related to dosing of JAK inhibitors and proper management of adverse drug reactions (ADRs).
Metrics
References
Lee JE, Kim IJ, Cho MS, Lee J. A Case of Rheumatoid Vasculitis Involving Hepatic Artery in Early Rheumatoid Arthritis. J Korean Med Sci. 2017;32((7)):1207-10.
Fox CQ, Ahmed SS. Physician Assistant's Clinical Review Cards. Philadelphia: F. A. Davis Company. 2002;138-9.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365((23)):2205-19.
Chaudhari K, Rizvi S, Syed BA. Rheumatoid arthritis: current and future trends. Nat Rev Drug Discov. 2016;15(5):305-6.
Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A. One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(4):551-8.
Henderson B, Pettipher ER. Arthritogenic Actions of Recombinant IL-1 and Tumour Necrosis Factor Alpha in the Rabbit: Evidence for Synergistic Interactions between Cytokines In Vivo. Clin Exp Immunol. 1989;75:306-10.
Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New Players in the Field of Immune-Mediated Diseases, beyond Rheumatoid Arthritis. Rheumatology (Oxford). 2019;58:i43-54.
WebMD. JAK Inhibitors for Rheumatoid Arthritis. Available at: https://www.webmd.com/rheumatoid-arthritis/jak-inhibitors-rheumatoid-arthritis. Accessed on 20 October 2023.
Arthritis Health. Risk factors for Rheumatoid Arthritis. 2021. Available at: https://www.arthritis-health.com/types/rheumatoid/risk-factors-rheumatoid-arthritis-ra. Accessed on 20 October 2023.
Dargham SR, Zahirovic S, Hammoudeh M, Al Emadi S, Masri BK, Halabi H, et al. Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients. PLoS One. 2018;13(12):e0208240.
Iwata S, Tanaka Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Exp Rev Clin. Immunol. 2016;12:1047-57.
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509.
Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017;77:1987-2001.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-62.
Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89.
Boyce EG, Vyas D, Rogan EL, Valle-Oseguera CS, O'Dell KM. Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies. Patient Relat Outcome Meas. 2016;7:1-12.
Clinical Trails.gov. A Study of Baricitinib in Participants With Rheumatoid Arthritis. Available at: https://clinicaltrials.gov/ct2/show/NCT04086745. Accessed on 20 October 2023.
Reich K, Kabashima K, Peris K. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020;156(12):1333-43.
Conaghan PG, Mysler E, Tanaka Y, Da Silva-Tillmann B, Shaw T, Liu J, et al. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. Drug Saf. 2021;44(5):515-30.
Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors: New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology. 2019;58(1):43-54.
Rajasimhan S, Pamuk O, Katz JD. Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk. Drugs Aging. 2020;37(8):551-8.
Samuel C, Cornman H, Kambala A, Kwatra SG. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatol Ther (Heidelb). 2023;13(3):729-49.
Massalska M, Maslinski W, Ciechomska M. Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. Cells. 2020; 9(8):1876.
Food and Drug Administration. Baricitinib. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2018/207924s000lbl.pdf. Accessed on 20 October 2023.
Food and Drug Administration. Tofacitinib. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2018/203214s018lbl.pdf. Accessed on 20 October 2023.
Food and Drug Administration. Upadacitinib. Available at: accessdata.fda.gov/drugsatfda_docs/ label/2019/211675s000lbl.pdf. Accessed on 20 October 2023.
Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care. Clin Ther. 2011;33:679-707.
Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis. JAMA Am Med Assoc. 2018;320:1360-72.
Wang D, Li Y, Liu Y, Shi G. The use of biologic therapies in the treatment of rheumatoid arthritis. Curr Pharm Biotechnol. 2014;15:542-8.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-99.
Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 2016;32:29-33.
Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S, Kola B. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. Adv Ther. 2018;35(10):1535-63.
Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333-40.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-62.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77.
Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016;2016(5):CD012183.
Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Maxwell LJ, Buchbinder R, et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;3(3):CD012591.
Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. Clin Ther. 2016;38(12):2628-41.
Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G. Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. Int J Rheumatol. 2017;8417249.
Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020;6(1):e001174.
Reed GW, Gerber RA, Shan Y, Takiya L, Dandreo KJ, Gruben D, et al. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis. Rheumatol Ther. 2019;6(4):573-86.
